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Abstract: Background: Neuropathic pain is defined by International Association for the 
Study of Pain (IASP) as “Pain caused by a lesion or disease of the somatosensory nervous 
system”. Elderly patients generally have high incidence of chronic neuropathic pain. The 
safe and effective treatment for chronic pain is a large public health concern. 
Palmitoylethanolamide (PEA) is an endogenously produced amide cannabimimetic 
compound with tissue protection and anti-inflammatory activity. Objectives: The aim & 
objective of this study is to evaluate the effectiveness and safety of Palmitoylethanolamide 
(PEA) in patients suffering from Neuropathic/Chronic Pain. Study Designed: Prospective 
Study. Materials and Methods: The Study was conducted in the Neurosurgery unit of 
Surgery Department in Gandhi Medical College & Associated Hamidia Hospital, Bhopal. 
A total no. of 150 patients aged 20-78 years were included in the study and divided into 
two groups, group I (Study group) and the group II (Control group) PEA was given to 
group I to evaluate the effect of PEA in neuropathic pain. Result: We  studied 150 patients 
with PEA for 60 days in a dose of 354 mg orally three times (TDS) a day for first 10 days 
and then two times (BID) a day for 50 days. It is available in India by the name of 
Palmiges. PEA was associated with greater pain reduction in the study group compared 
to the placebo controlled group. The primary outcome measured was the mean pain 
reduction evaluated by VAS scale. Conclusion: PEA seems to be useful in the treatment 
of neuropathic / chronic pain and it is well tolerated in patients in study group. Palmiges 
PEA reduces the inflammation in neuropathic pain, which results in lowering/reduction 
of neuropathic pain. Controlled trials are further needed to prove efficacy and reliability 
and also to find out the adverse reaction associated with the drug.  
Key words: PEA, Palmitoylethanolamide, Neuropathic Pain, Analgesics, VAS (Visual 
Analogue Score) 
 
Introduction 
Neuropathic Pain is a complex condition 
that has its origin in a primary lesion or 
dysfunction of any part of the nervous system 
from the peripheral receptor to the brain. 
Persistent neuropathic pain often interferes 
with sleep, work, recreational activities and the 
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emotional state of the individual who suffers 
from it, thus affecting quality of life [1]. 
Neuropathic pain is usually described as the 
perception of strange or unusual painful 
sensations like burning, stabbing or lancing 
pains experienced as electrical discharges or 
other painful sensations [2,3] . Neuropathic 
pain may be evoked by mechanical, thermal or 
chemical stimuli. 
The Global Prevalence: reported in the 
literature 
•A review of the epidemiology of chronic 
pain found that there is still no accurate 
estimate available for the population 
prevalence of neuropathic pain (Smith et 
al.2012). [4] 
•Overall, neuropathic pain affects 7-10% of 
the general population. 
•In the primary care setting, the prevalence 
has been reported to be between 2 to 11%.  
•By Neuropathy Symptom Score (NSS) 
and Neuropathy Disability Score (NDS) 
criteria, the prevalence of DPN was 29.2%.  
•In cancer patients the prevalence is 19%.  
In Indian Scenario: - 
•The prevalence of Neuropathic pain in 
Indian scenario is difficult to establish, as there 
are many confounding factors that may lead to 
under reporting of neuropathic pain. 
•The prevalence in males is around 26.1% 
and females is 33.8%, whereas prevalence of 
neuropathic pain in cancer patients is 19%. 
•About 1% to 37% of chronic lower back 
pain patients may have a neuropathic 
component related to it. 
•Prevalence of neuropathic pain in low 
backache-related leg pain (LBLP) patients 
varies from 19% to 80%. 
•A study done by Ind INEP study group in 
Indian patients in the year 2008 suggests that 
painful diabetic neuropathy is the most 
common cause of neuropathic pain (72%). 
•Ind INep study group also suggests that, 
about 50% of patients reported co-morbid 
mood disorders, while 67% reported 
medication-related adverse event in the 
preceding week. 
Inflammation:  
Inflammation is the response of living 
tissue to injury. It involves a well-organized 
cascade of fluid and cellular changes within 
living tissue. The inflammatory process is of 
great significance in the development of 
Neuropathic Pain (NP) [5]. PEA, an 
endogenously produced amide has been 
established to work on the inflammatory 
pathways acting as a pacifier against 
inflammation. In neuropathic pain, the 
amount of the amide reduces drastically in the 
body resulting in aggravated inflammation 
and furtherance of diseased condition [6] . The 
endogenously produced FAAH (Fatty Acid 
Amide Hydrolase) enzyme further degrades 
the available amide, further reducing its 
quantity and effectiveness. Palmiges (PEA) is 
an endogenously produced amide. PEA, 
Genistein and Daidzein function to counter 
the action of FAAH enzyme, thereby 
improving the condition of aggravated 
inflammation, which is the root cause of 
neuropathic pain [7]. 
Current treatment modalities and their 
Drawbacks: 
•Current treatment drugs such as 
gabapentin, pregabalin and duloxetine etc. 
have annoying side effects such as drowsiness, 
dizziness, blurred vision, somnolence, 
peripheral edema etc. Moreover, using these 
drugs in the long term causes desensitization 
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of neuron receptors. Therefore, the dose of 
these drugs has to be increased to elicit the 
desired response and that leads to more 
number of side effects. In addition, some drugs 
require dose adjustment in renal impairment. 
Hence, the current treatment paradigms have 
some gaps and require some new arsenal to 
fight against neuropathic pain. Thus, what is 
needed at this critical juncture is a solution 
which corroborates to the core of neuropathic 
pain with no side effects. 
PALMIGES contains the following 
components:  
A. Palmitoylethanolamide (PEA): 
•PEA is considered an endogenous 
Peroxisome Proliferator Activated Receptors 
(PPAR) agonist or activator, interacting with 
this receptor to inhibit inflammatory pathways 
& oxidative stress. 
•During neuropathic pain, PEA can 
modulate the PPAR pathway that is able to 
attenuate Nuclear Factor Kappa B cells 
(NFKB) induced inflammatory factors or 
tumor necrosis factor (IL-1 or TNF), inhibit 
infiltration and activation of MC, reduce 
mesangial matrix proliferation induced by 
reactive oxidative stress (ROS) which then 
resulted in albuminuria [8] . 
B. Genistein: 
•Genistein is a FAAH inhibitor that not 
only prevents the degradation of PEA from 
FAAH enzyme in the body but also exerts 
synergistic effect with PEA to reduce oxidative 
stress in the over- inflamed neuronal cells. 
C. Daidzein: 
•Daidzein belongs to the class of 
isoflavones and serves as a potent FAAH 
inhibitor in conjunction with Genistein. It 
works as a competitive binder to FAAH 
disallowing it to degrade the externally 
supplemented PEA. 
D. MPFAITECH: A technology to ensure 
the proprietary blend is presented in a form 
that could be easily absorbed in the human 
body. 
Palmitoylethanolamide (PEA) is a 
cannabimimetic compound which reduces 
neuropathic pain. It is a special food for 
medical purpose in the treatment of chronic 
pain.  
Material and Methods 
The study includes patients with 
neuropathic pain and pain due to various 
causes like chemo-therapy induced 
neuropathic pain, chronic pain, trigeminal 
neuralgia, lower back pain and cervical 
spondylosis pain etc. These patients reported 
in the outpatient department (OPD) of 
Neurosurgery of Hamidia Hospital Bhopal. In 
a period of four months total 150 patients with 
neuropathic pain between age group of 20-78 
years were studied. Male patients were 94 and 
female patients were 56.  They were divided 
into two groups each consisting of 75 patients. 
The control group received usual conventional 
treatment like NSAID’s, antiepileptics 
(Carbamazepine, Gabapentein or Pregabalin 
etc.), SNRIs (Duloxetine), Opioids 
(Acetaminophen, tramadol, tapendol etc.) or 
TCAS (Amitriptolene, Nortreptolene). The 
study group patients received PEA (Palmiges) 
daily, three times a day for 10 days (TDS), and 
then two times a day (BID) for 50 days. 
Patients were allowed to continue with their 
usual treatment if they had other 
comorbidities. Pain reduction was more 
evident in group I (study group) treated with 
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PEA as compared to controlled group.    
Source of data: 150 patients were examined 
and treated on OPD basis in the Neurosurgery 
OPD of Hamidia Hospital Bhopal from Oct 
2017 to Feb 2018 and 14 Patients were 
admitted in the Neurosurgery Unit of Surgery 
Department.  
Discussion 
Neuropathic Pain can be treated with 
neuroepileptics, antidepressants and opioids 
whereas musculoskeletal pain can be treated 
with acetaminophen and non-steroidal anti-
inflammatory (NSAID) drugs. Chronic use of 
analgesics is often limited by side effect, 
toxicity and diminished patient compliance 
and is a problem, especially in older patients. 
Neuropathic pain results from damage or 
disease affecting the somatosensory system. 
Up to 7-8% of the western population is 
affected and in 5%, it may be severe also. 
Treatment of neuropathic pain is challenging 
because about 50% of patients with 
neuropathic pain get partial relief from 
treatment which currently comprises of 
opioids, NSAIDS, and antiepileptics etc. So the 
choice of treatment for neuropathic pain 
should always be taken into consideration, 
besides efficacy, safety and tolerability of the 
treatment and interaction with other 
concomitant treatments. 
The draw backs of current drugs in 
neuropathic pain and need of new solution: 
Current treatment options for neuropathic 
pain are mainly focused on neuronal system 
suppressing GABA or other inhibitory 
receptors. Most of the drugs used for 
neuropathic pain cause drowsiness, dizziness, 
blurred vision, somnolence, peripheral edema, 
psychomotor slowing and paresthesia and 
many more. Moreover, using these drugs on 
long term basis causes desensitization of 
receptors. Therefore, there is an increase in the 
dose of these drugs to elicit the desired 
response and that leads to more number of 
side effects. In conclusion, the current 
treatment paradigms have some gaps and 
require some new arsenal to fight against 
neuropathic pain.  
The second described treatment is PEA. 
PEA has high affinity to the nuclear 
peroxisome proliferator activated receptors α 
(PPAR-α) and PEA has indeed analgesic and 
anti- inflammatory effects in clinical trials. 
Biosynthesis of PEA in tissues, live neurons 
and glial cells occurs in inflammatory and 
chronic pain states [9].  When given orally, 
PEA has almost no side effect, though it has 
clear pain reducing properties in various pain 
states [10].  
It seems that PEA reduces pain via the 
natural modulation pathway and besides 
modulation of the central nervous system, 
through the release of endorphins, serotonin, 
norepinephrine and dopamine. Pain reducing 
effects of acupuncture can also be explained by 
suppression of activated glial cell [11]. PEA 
may have a synergistic effect in modulating 
glial cells, mast cells and neurons [12s]. We 
often observe pain reduction when we add 
PEA to our treatment. PEA also enhances the 
analgesic effect of compounds such as 
pregabalin and amitriptyline.  
In 1986, the famous neuroscientist 
professor Erminio Costa delivered a key note 
lecture in Washington, bearing the title “To 
follow where nature leads”. In this speech 
Costa talked with great vision about how 
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nature itself can become our tutor in 
developing new drugs. PEA is one of these 
molecules entering clinical use and developed 
according to Costa’s vision. That is why PEA 
seems such a good compound to combine with 
other treatment modalities. 
Result 
PEA (palmitoylethanolamide) generally 
provided better pain relief than placebo in a 
comparison that includes three different 
chronic neuropathic pain conditions 
(trigeminal neuralgia, diabetic neuropathy and 
cervical pain). There was some indication of 
pain improvement, mainly over the short 
term, but with poorly defined outcome. The 
mean decrease on the VAS was largest in the 
study group: a reduction from 7.1 to 2.1 which 
is more than 50% pain reduction. In the 
control group, the VAS score decreased from 
6.6 to 4.6. 
PEA resulted in a significant reduction in 
pain symptoms in neuropathic pain after 7 
weeks (49 days). The median values obtained 
from TSS (Total Symptom Score) and NSPI 
(Neuropathic Pain Symptoms Inventory) were 
compared to base level at many observation 
points until the end of treatment at 60 days 
confirming a significant attenuation (P<0.001) 
in the intensity and presence of symptoms. 
After completion of treatment i.e. after 60 days 
the same significant reduction (P<0.001) was 
seen in relation to the frequency and intensity 
of symptoms like pain, burning, numbness 
and paresthesia. 
What we have is an indication that PEA can 
produce good level of pain relief for some 
patients with distressing chronic painful 
conditions.  
 
 
Figure 1 - 50% decrease in VAS in study and control groups 
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Figure 2 - The mean decrease on the VAS was largest in the study group: a reduction from 7.1 to 2.1 which is 
more than 50% pain reduction. In the control group the VAS score decreased from 6.6 to 4.6 
 
 
Figure 3 - Effect of  PEA on painful neuropathy evaluated by Michigan Neuropathy Screening Instrument 
(MNSI),  Neuropathic Pain Symptoms Inventory (NPSI) and Total Symptom Score (TSS),. Analysis of variance 
shows a significantly decreased pain intensity and symptom scores observed by MNSI, TNPSI and TSS (𝑃 < 
0.0001) during the treatment period 
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Figure 4 - Effect of micronized PEA on each neuropathic pain symptom assessed by Total Symptom Score (TSS). 
The intensity and frequency evaluated by TSS, show a significant mitigation (𝑃 < 0.0001) after 60 days of 
treatment compared to baseline. This effect was persistent even after one month of treatment discontinuation 
 
In this study the important observation is 
that a clinical and statistical difference was 
found that after 7 weeks (49 days) and onset of 
pain reduction was at 2 weeks (14 days) but the 
pain reduction at 7th week was satisfactory. 
These observations support the 
recommendation to use PEA for at least 2 
months before evaluating the result.  
Overall completeness and applicability of 
evidence available include: 
•Limited Size 
•Short Duration 
•Inadequate Outcome 
•Incomplete Outcome Assessment 
In order to be sure that PEA works in 
neuropathic/chronic pain and to be confident 
of the magnitude of the effect, the ideal would 
be several large randomized double blind 
studies comparing PEA at sensible doses with 
placebo over 8 to 12 weeks. 
Conclusion 
Chronic pain management remains a 
challenge for the clinician.  PEA induced pain 
relief is progressive, age and gender 
independent and not related with the 
etiopathogenesis of chronic pain. PEA also 
controls the mechanism common to different 
conditions where neuropathic pain is 
associated e.g. neuro inflammation. 
PEA is safe and well tolerated treatment for 
control/reduction of chronic neuropathic pain 
and can be combined with other 
standard/routinely used analgesic 
medications. PEA possesses intrinsic efficacy 
towards syndromes co-morbid with chronic 
pain e.g. depression and anxiety. PEA also 
lacks acute and chronic toxicity and is not 
associated with gastric mucosal lesions. That is 
why it has become possible to include PEA in 
 
 
 
 
 
Romanian Neurosurgery (2018) XXXII 4: 654 - 661 | 661 
 
 
 
 
 
 
 
new class of therapeutic agent called food for 
special medical purposes “FSMP”. PEA is safe 
and well tolerated treatment for the reduction 
of neuropathic pain and can easily be 
combined as well added to classical 
medication without fear of negative 
interactions. 
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